Bruce Goodwin is the Managing Director of Janssen, the pharmaceutical companies of Johnson & Johnson, in Australia and New Zealand (Janssen-Cilag Pty Ltd). Bruce’s career with the Johnson & Johnson family of companies spans thirty-five years including roles outside his home country of Australia, in Janssen Japan, Janssen Belgium and Janssen United Kingdom.
He has been in General Management roles for the last ten years including two terms in his current role, and also three years as President and Representative Director Janssen Japan.
Prior to General Management, he has held Management Board Director positions in Sales and Marketing and in Finance, as well as having gained valuable experience in Global Licensing and Acquisitions roles.
With over thirty-five years’ experience, Bruce is a respected Industry Leader and is currently an elected Director and Board Member of Medicines Australia. In addition, while in Japan, Bruce held the position of the Vice Chair of the Japan Based Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines, as a member of the Cancer Drugs Access Committee in 2017 and more recently with his appointment as a Director and Board member of the Australian Genomic Cancer Medicine Centre.
Bruce holds a Bachelor of Economics degree from Macquarie University, a Master of Business Administration (MBA) from Macquarie Graduate School of Management and is a Graduate Member of the Australian Institute of Company Directors (AICD).